ArticleAlzheimer's & dementia (Amsterdam, Netherlands)2020
Proteomic profiles of incident mild cognitive impairment and Alzheimer's disease among adults with Down syndrome.
Article in Alzheimer's & dementia (Amsterdam, Netherlands), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Blood-based biomarkers for Alzheimer's disease in Down syndrome: A systematic review and meta-analysis.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Pooled it
- Blood biomarkers in Down syndrome: Facilitating Alzheimer's disease detection and monitoring.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Review
- Integrated analysis of immunometabolic interactions in Down syndrome.Science advances · 2024Article
- Comorbidities Incorporated to Improve Prediction for Prevalent Mild Cognitive Impairment and Alzheimer's Disease in the HABS-HD Study.Journal of Alzheimer's disease : JAD · 2023Article
- Combination of Serum and Plasma Biomarkers Could Improve Prediction Performance for Alzheimer's Disease.Genes · 2022Article
- Characterizing plasma NfL in a community-dwelling multi-ethnic cohort: Results from the HABLE study.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2022Article
- Accelerating Hyperparameter Tuning in Machine Learning for Alzheimer's Disease With High Performance Computing.Frontiers in artificial intelligence · 2021Review
- Recursive Support Vector Machine Biomarker Selection for Alzheimer's Disease.Journal of Alzheimer's disease : JAD · 2021Article
- Proteomic profiles of incident mild cognitive impairment and Alzheimer's disease among adults with Down syndrome.Alzheimer's & dementia (Amsterdam, Netherlands) · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
introductionWe sought to determine if proteomic profiles could predict risk for incident mild cognitive impairment (MCI) and Alzheimer's disease (AD) among adults with Down syndrome (DS).
methodsIn a cohort of 398 adults with DS, a total of n = 186 participants were determined to be non-demented and without MCI or AD at baseline and throughout follow-up; n = 103 had incident MCI and n = 81 had incident AD. Proteomics were conducted on banked plasma samples from a previously generated algorithm.
resultsThe proteomic profile was highly accurate in predicting incident MCI (area under the curve [AUC] = 0.92) and incident AD (AUC = 0.88). For MCI risk, the support vector machine (SVM)-based high/low cut-point yielded an adjusted hazard ratio (HR) = 6.46 ( DISCUSSION: The current results provide support for our blood-based proteomic profile for predicting risk for MCI and AD among adults with DS.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.